Laboratory Equipment reports that Lilly is moving its ImClone research headquarters (which specializes in developing cancer biologics) into a new biopharmaceutical research cluster in New York, and just one year after Lilly completed construction of its biotechnology R&D complex at its headquarters in Indianapolis.
"We're moving full speed ahead toward building a biotechnology powerhouse," says John Lechleiter, Lilly chairman/CEO. "The science, technology and talent at our new center in San Diego will help bring novel biotech medicines to patients faster and more efficiently, and reinforces Lilly's commitment and contributions to San Diego's burgeoning bioscience industry."
What do you think of Lilly's move out West? Will it be a step in the right direction for their bio offerings?
|
Share this article with your social network, just click below to share now!
|
|
|
No comments :
Post a Comment